GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

Contributed by: Business Wire

Logo

Images

First-in-human contrast enhanced MRI images with GE HealthCare's mangaciclanol

Business Wire embedded0

Tags

Science

Biotechnology

Research

Pharmaceutical

Health

FDA

Medical Devices

Clinical Trials

novel imaging agents

More Like This

A radiologist looking at MRI exam images (Photo: Business Wire)

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

PR Newswire associated0

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire)

GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

PR Newswire associated0

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

PR Newswire associated0

New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission

PR Newswire associated0

Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union

PR Newswire associated0

The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age

PR Newswire associated0

The CHMP adopted a positive opinion for Vueway® (gadopiclenol) for its use in pediatric patients under 2 years of age